Amylyx Pharmaceuticals (AMLX) Cost of Revenue (2022 - 2024)
Historic Cost of Revenue for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Q2 2024 value amounting to $8000.0.
- Amylyx Pharmaceuticals' Cost of Revenue fell 9985.66% to $8000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $8000.0, marking a year-over-year decrease of 9996.94%. This contributed to the annual value of $6.0 million for FY2024, which is 7660.08% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Cost of Revenue stood at $8000.0 for Q2 2024, which was down 9985.66% from $5.9 million recorded in Q1 2024.
- In the past 5 years, Amylyx Pharmaceuticals' Cost of Revenue registered a high of $9.4 million during Q4 2023, and its lowest value of $8000.0 during Q2 2024.
- In the last 3 years, Amylyx Pharmaceuticals' Cost of Revenue had a median value of $5.3 million in 2023 and averaged $4.3 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Cost of Revenue skyrocketed by 293372.09% in 2023 and then crashed by 9985.66% in 2024.
- Over the past 3 years, Amylyx Pharmaceuticals' Cost of Revenue (Quarter) stood at $2.8 million in 2022, then surged by 231.8% to $9.4 million in 2023, then plummeted by 99.91% to $8000.0 in 2024.
- Its Cost of Revenue was $8000.0 in Q2 2024, compared to $5.9 million in Q1 2024 and $9.4 million in Q4 2023.